Erratum: EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases (European Journal of Nuclear Medicine and Molecular Imaging DOI: 10.1007/s00259-007-0407-4);EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 8, 2007, Pages 1324-1327

  Tennvall, Jan ^a   Brans, Boudewijn ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

32P phosphate; Essential thrombocythaemia; Guidelines; Nuclear medicine; Polycythaemia vera; Radionuclide therapy

Indexed keywords

BUSULFAN; CHLORAMBUCIL; HYDROXYUREA; PHOSPHATE PHOSPHORUS 32; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

HUMAN; MYELOPROLIFERATIVE DISORDER; NUCLEAR MEDICINE; PHYSICIAN; POLYCYTHEMIA VERA; PRACTICE GUIDELINE; REVIEW; THROMBOCYTHEMIA;

EID: 34548078380     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0484-4     Document Type: Erratum

References (5)

1. 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood 1997;89(7):2319-27.
2. Brandt L, Anderson H. Survival and risk of leukaemia in polycythemia vera and essential thrombocythemia treated with oral radiophosphorus. Eur J Haematol 1995;54(1):21-6.
3. Fruchtman SM. Treatment paradigms in the management of myeloproliferative disorders. Semin Hematol 2004;41 (2 suppl 3):18-22.
4. Barbui T. The leukaemia controversy in myeloprolifertive disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Semin Hematol 2004;41 (2 Suppl 3):15-7.
5. Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A. Anagrelide Study Group. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leukemia Res 2005;29:481-91.